Previous 10 | Next 10 |
Bright Minds Biosciences ( NASDAQ: DRUG ) said it had received a letter from the Nasdaq stating that following the resignation of Williamson from the company’s board of directors and audit committee, the Company no longer complies with its independent director and audit commit...
VANCOUVER, British Columbia, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”) announces that it has received a letter (the “ Deficiency Letter ”) from the Nasdaq Sto...
Bright Minds ( NASDAQ: DRUG ) said it received a notification from the Nasdaq that it was not in compliance as its shares were below the minimum bid price requirement of $1.00 per Share. The company has 180 calendar days, or until July 25, to regain compliance. DRUG ...
VANCOUVER, British Columbia, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:DRUG) (“ Bright Minds ” or the “ Company ”) announces that it has received a notification letter (the “ Notification Letter ”) from...
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on developing novel drugs for the targeted treatment of neuropsych...
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Dec. 02, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (NASDAQ:...
Despite the challenges of raising capital these days in the cannabis and psychedelics industry, two companies managed to close deals before the end of the year. Trees The Canadian-based Trees Corporation (NEO: Tree) completed the closing of a non-brokered private placeme...
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British Columbia, Nov. 28, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE:DRUG) (N...
-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Today’s continued rally across equity markets is providing a bullish lift to many investors who have had their sentiment beat down to a great degree this year. While broad-based, certain sectors of the market are ral...
News, Short Squeeze, Breakout and More Instantly...
Bright Minds Biosciences Inc. Company Name:
DRUG Stock Symbol:
NASDAQ Market:
Bright Minds Biosciences Inc. Website:
Algoma Steel Group Inc. (ASTL) is expected to report for Q3 2024 CTS Corporation (CTS) is expected to report for Q4 2023 Xylem Inc. New (XYL) is expected to report $0.96 for Q4 2023 TIM S.A. American Depositary Shares (Each representing 5) (TIMB) is expected to report for Q4 2023 ...
Bright Minds Biosciences Inc. (DRUG) is expected to report for quarter end 2023-12-31